2022 the Japanese Society of Medical Oncology Annual Meeting

Presentation information

Print

Mini-Oral Session

[MO34] Mini-Oral Session 34　Translational Research / Clinical Pharmacology 5（Basic science, Biomarker）
【E】

Sat. Feb 19, 2022 2:00 PM - 2:40 PM Room 5 (Room B-1, 2F, Kyoto International Conference Center)

Chair：Toshio Shimizu（Early Phase 1 Drug Development Service, Department of Experimental Therapeutics, National Cancer Center Hospital），Yoshihiko Segawa（Department of Medical Oncology, International Medical Center, Saitama Medical University）

[MO34-3] MORAb-202, a novel ADC, can overcome chemo-resistance derived from the FOLRα-PHB2-MDM2 axis

○Hisato Kawakami1, Hitomi Sakai2, Takeshi Teramura3, Yuta Onodera3, Elizabeth Somers4, Keiji Furuuchi5, Toshimitsu Uenaka5, Ryoji Kato1, Kazuhiko Nakagawa1 (1.Department of Medical Oncology, Kindai University Faculty of Medicine, 2.Advanced Cancer Translational Research Institute, Showa University, 3.Division of Cell Biology for Regenerative Medicine, Institute of Advanced Clinical Medicine, Kindai University Faculty of Medicine, 4.AD Franchise Special Mission, 5.Epochal Precision Anti-Cancer Therapeutics (EPAT), Eisai Inc.)

Abstract password authentication.
The password can be found on page 27 of the program book.

Password